These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34031863)

  • 21. CCL2-CCR2 signaling axis in obesity and metabolic diseases.
    Wu Y; Ma Y
    J Cell Physiol; 2024 Apr; 239(4):e31192. PubMed ID: 38284280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCL2/CCR2 signaling pathway in glioblastoma multiforme.
    Vakilian A; Khorramdelazad H; Heidari P; Sheikh Rezaei Z; Hassanshahi G
    Neurochem Int; 2017 Feb; 103():1-7. PubMed ID: 28025034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CCL2/CCL7/CCL12/CCR2 pathway is substantially and persistently upregulated in mice after traumatic brain injury, and CCL2 modulates the complement system in microglia.
    Popiolek-Barczyk K; Ciechanowska A; Ciapała K; Pawlik K; Oggioni M; Mercurio D; De Simoni MG; Mika J
    Mol Cell Probes; 2020 Dec; 54():101671. PubMed ID: 33160071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
    Zhuang H; Cao G; Kou C; Liu T
    Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the chemokine ligand 2-chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain.
    Liu S; Lan XB; Tian MM; Zhu CH; Ma L; Yang JM; Du J; Zheng P; Yu JQ; Liu N
    Eur J Pharmacol; 2023 May; 947():175646. PubMed ID: 36907261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic insights into the role of the chemokine CCL2/CCR2 axis in dorsal root ganglia to peripheral inflammation and pain hypersensitivity.
    Dansereau MA; Midavaine É; Bégin-Lavallée V; Belkouch M; Beaudet N; Longpré JM; Mélik-Parsadaniantz S; Sarret P
    J Neuroinflammation; 2021 Mar; 18(1):79. PubMed ID: 33757529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemokine (C-C Motif) Ligand 2/Chemokine Receptor 2 (CCR2) Axis Blockade to Delay Chondrocyte Hypertrophy as a Therapeutic Strategy for Osteoarthritis.
    Wang Z; Wang B; Zhang J; Wu Z; Yu L; Sun Z
    Med Sci Monit; 2021 Dec; 27():e930053. PubMed ID: 34876548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.
    Parillaud VR; Lornet G; Monnet Y; Privat AL; Haddad AT; Brochard V; Bekaert A; de Chanville CB; Hirsch EC; Combadière C; Hunot S; Lobsiger CS
    J Neuroinflammation; 2017 Mar; 14(1):60. PubMed ID: 28320442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.
    Yumimoto K; Sugiyama S; Mimori K; Nakayama KI
    Cancer Sci; 2019 Jul; 110(7):2090-2099. PubMed ID: 31111571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into CC Chemokine Ligand 2/Chemokine Receptor 2 Molecular Recognition: A Step Forward toward Antichemotactic Agents.
    David KS; Oliveira ERA; Horta BAC; Valente AP; de Paula VS
    Biochemistry; 2017 Jun; 56(25):3197-3210. PubMed ID: 28570817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases.
    Gholamalizadeh H; Ensan B; Sukhorukov VN; Sahebkar A
    J Pharm Pharmacol; 2024 Jan; 76(2):138-153. PubMed ID: 38127312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.
    Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD
    J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
    Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
    Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemokine CCL2-CCR2 Signaling Induces Neuronal Cell Death via STAT3 Activation and IL-1β Production after Status Epilepticus.
    Tian DS; Peng J; Murugan M; Feng LJ; Liu JL; Eyo UB; Zhou LJ; Mogilevsky R; Wang W; Wu LJ
    J Neurosci; 2017 Aug; 37(33):7878-7892. PubMed ID: 28716963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The chemokine (CCL2-CCR2) signaling axis mediates perineural invasion.
    He S; He S; Chen CH; Deborde S; Bakst RL; Chernichenko N; McNamara WF; Lee SY; Barajas F; Yu Z; Al-Ahmadie HA; Wong RJ
    Mol Cancer Res; 2015 Feb; 13(2):380-90. PubMed ID: 25312961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
    Fei L; Ren X; Yu H; Zhan Y
    Front Immunol; 2021; 12():771210. PubMed ID: 34804061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CCL2-CCR2 system affects the progression and clearance of intracerebral hemorrhage.
    Yao Y; Tsirka SE
    Glia; 2012 May; 60(6):908-18. PubMed ID: 22419223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCR2: A characteristic chemokine receptor in normal and pathological intestine.
    Yuan J
    Cytokine; 2023 Sep; 169():156292. PubMed ID: 37437448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues.
    Abbasifard M; Khorramdelazad H
    Front Immunol; 2024; 15():1387651. PubMed ID: 39076996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.